Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 12/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562673 | 0.87 | PARP1 (0.49) | RIPK1PARP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1562671 | 0.87 | PARP1 (0.49) | RIPK1PARP1ALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL4797679 | 0.86 | PARP1 (0.47) | RIPK1PARP1ALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL2235593 | 0.86 | PARP1 (0.47) | RIPK1PARP1ALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL2235597 | 0.86 | PARP1 (0.47) | RIPK1PARP1ALDH1A1HPGDHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL15956777 | 0.84 | NR3C2 (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL17332759 | 0.83 | KIF11 (0.38) | RIPK1ALDH1A1HPGDHSD17B10KDM4E | |
| Trifluoroacetic Acid SCHEMBL15565133 | 0.83 | KMT2A (0.39) | RIPK1HSD17B10KDM4EALOX15GAA | |
| Trifluoroacetic Acid SCHEMBL15565162 | 0.83 | NR3C1 (0.39) | — | |
| Trifluoroacetic Acid SCHEMBL31663497 | 0.81 | PTPN7 (0.34) | RIPK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2882725-A1 | SUBSTITUTED HETERO-AZEPINONES | F. Hoffmann-La Roche AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-7425550-B2 | Lactam glycogen phosphorylase inhibitors and method of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-09-16 | — | — | US | disclosed |
| US-7098235-B2 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | SHER PHILIP | 2006-06-15 | — | — | US | disclosed |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | RIPK1 2747/4885PARP1 122/4885ALDH1A1 2459/4885 |
| US-20040142938-A1 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds | PYGL, PNLIP, PYGM | RIPK1 3009/4885PARP1 1060/4885ALDH1A1 2808/4885 |
| US-20060128687-A1 | Lactam glycogen phosphorylase inhibitors and method of use | PYGL, PYGM, GYS1 | RIPK1 2109/4885PARP1 1629/4885ALDH1A1 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.